COVID-19 Lessons to Inform Pandemic Influenza Response

Public Workshop
May 18, 2021

Speaker Biographies

Celia Alpuche Aranda, M.D., Ph.D., is a physician, specialized in Pediatric Infectious Diseases. She also graduated from a Masters and a PhD in Medical Sciences-Microbiology from National Autonomous University of Mexico (UNAM) School of Medicine and later she was a Post-Doctoral Fellow at the Infectious Diseases Unit of the Massachusetts General Hospital-Harvard Medical School (1990-1994). She worked at the Hospital Infantil de México Federico Gómez (HIMFG); Mexico City as Infectious Disease attending physician and Chief Department of Enteropathogens Laboratory (1995-1997), later she was the coordinator of the Laboratory of Infectious diseases and Clinical Microbiology of the Experimental Medicine Department- Medical School-UNAM (1997-2006). Afterward she became Director of the Institute for Epidemiological Diagnosis and Reference (InDRE) of the MOH Mexico (2007-2012), where she joined the epidemiological surveillance of the country and a key element in 2009 influenza pandemic response. His main contribution directing InDRE was the reorganization and improvement of the infrastructure and technology in support of diagnosis for the epidemiological surveillance of the country, including the project of the new modern building of the reference laboratory and the development of molecular technology in the entire network of public health laboratories in the country. She is currently the director of the INSP Center for Infectious Diseases Research (2013-). She participates in technical-consultant and advisory groups at the national and international levels (PAHO, WHO, United Nations, etc.) in areas of antimicrobial resistance, vaccine-preventable and emerging diseases, allege use of biological weapons, among others. She has been the thesis director for undergraduate, master's and PhD students. His research work has been publishing in more than 100 peer review manuscripts. Her field of work is on bacterial pathogenesis, epidemiology and molecular bases of antimicrobial resistance, new diagnostic techniques and dynamics of transmission of vaccine-preventable and emerging diseases such as influenza, Dengue, Chikungunya and Zika and currently helping MOH in the response to COVID-19 (areas of diagnostic and vaccines).

Gian-Luca Burci, Ph.D., is an Adjunct Professor of international law at the Graduate Institute of International and Development Studies, Geneva since 2012. Since 2016, Prof. Burci is Visiting Professor and Senior Scholar at the O’Neill Institute on National and Global Health Law, Georgetown University School of Law. Before his appointment at the Graduate Institute, Dr. Burci served in the Legal Office of the World Health Organization from 1998 to 2016 and was its Legal Counsel from 2005 to 2016. Professor Burci previously worked in the Department of International Cooperation of the International Atomic
Energy Agency (1998-1999) and the Office of the Legal Counsel of the United Nations, where he was designated focal point for UN economic sanctions (1989-1998). During his service in WHO, he was involved among other issues in the revision and implementation of the International Health Regulations, WHO’s response to the 2009-2010 H1N1 influenza pandemic and the 2014-2016 Ebola outbreak, and institutional aspects of WHO reform. Prof. Burci holds a postgraduate degree in law from the University of Genova, Italy. His areas of expertise are public international law, the law and practice of international organizations as well as global health governance and law. Prof. Burci is the co-editor of the leading book on global health law.

**Dennis Carroll, Ph.D.**, has over 30 years of leadership experience in global health and development. Until recently he served as the Director of the U.S. Agency for International Development’s (USAID) Emerging Threats Division. In this position Dr. Carroll was responsible for providing strategic and operational leadership for the Agency's programs addressing new and emerging disease threats. He provided overall strategic leadership for the Agency’s response to the West Africa Ebola epidemic. He currently is a Senior Advisor on Global Health Security at URC and is the Chair of the Leadership Board of the Global Virome Project, an international partnership to build the systems and capacities to detect and characterize future viral threats while they are still circulating in wildlife - enabling the world to better prepare before they spill over into us.

**Peter Daszak, Ph.D.**, is the President and CEO of EcoHealth Alliance. His research uses epidemiology and mathematical modeling coupled with field and laboratory analyses to understand infectious disease emergence, especially wildlife-origin viruses. He has worked more recently on SARS, Nipah and Hendra, Ebola, and avian influenza viruses, while his earlier work was on wildlife diseases, including discovery of a fungal pathogen, chytridiomycosis, causing global amphibian population declines and extinctions. His policy interests are in global health, infectious disease surveillance, emerging diseases, biodefense, public health, as well as conservation medicine, One Health, EcoHealth and Planetary Health. He has developed a keen interest in gain-of-function issues, pandemic prediction and prevention, and infectious disease threats to low- and middle-income countries.

**Keiji Fukuda, M.D., MPH**, is Director and Clinical Professor at The University of Hong Kong School of Public Health. He previously worked at the World Health Organization (WHO) in Geneva as the Assistant Director-General (ADG) for Health Security, as the Special Adviser to the Director General for pandemic influenza and for antimicrobial resistance and as Director of the Global Influenza Program. Before that, he worked at the U.S. Centers for Disease Control and Prevention (CDC) as the Epidemiology Chief, Influenza Branch. At CDC, he led the first CDC field teams that investigated the emergence of influenza H5N1 in Hong Kong in 1997 and worked under WHO in China on the emergence and control of SARS in 2003. He oversaw CDC’s national influenza disease surveillance and contributed to US influenza vaccination guidelines and pandemic preparedness. At WHO, as ADG, he was responsible for WHO’s global response to the 2009 H1N1 influenza pandemic, for implementation of the International Health Regulations and the global influenza surveillance network and the influenza vaccine strain selection process. He led several field missions related to MERS in Saudi Arabia and Korea, Ebola in West Africa in 2014 and H5N1 in Egypt and was WHO’s technical lead on negotiations related to the
Pandemic Influenza Preparedness Framework (PIP F), the Global Health Security Agenda and antimicrobial resistance. He currently advises the Hong Kong Government on its COVID-19 response and vaccine related matters. He was a member of the Forum on Microbial Threats of the US National Academies of Sciences, Engineering, and Medicine and received his BA from Oberlin College (1978), MD from the University of Vermont (1984), MPH from the University of California, Berkeley (1989) and EIS training at CDC.

Youngmee Jee M.D., Ph.D is Chief Executive Officer of the Institut Pasteur Korea and also serves as Special Representative for Health Diplomacy, Korea Foundation. Dr Jee has broad experience in collaborating with WHO and international public health partners. From 2014 to 2019, she served as Director-General of the Center for Infectious Disease Research of the Korea Centers for Disease Control and led various international activities including the WHO-Korea Joint Mission on MERS Outbreak in 2015 and the WHO International Health Regulation (IHR) Joint External Evaluation (JEE) on national public health emergency response capacity in 2017. She received a President Medal of Distinguished Service in 2017. She also served as a member of the Board of Trustees of the International Vaccine Institute (2016-2019) and President of the Korean Society of Infectious Diseases (2017-2019). From August 2007 to October 2014, Dr. Jee worked as regional laboratory coordinator in the Expanded Programme on Immunization of the WHO Western Pacific Region. Dr. Jee's work at the WHO involved the coordination of extensive collaborations between public health laboratories and technical assistance to the poliomyelitis, measles/rubella and Japanese encephalitis network laboratories in the WHO Western Pacific Region with a view to ensuring a high-quality laboratory performance. Dr. Jee served as Chairperson of the National Poliomyelitis Certification Committee in the Republic of Korea from 2016 to 2020 and served as a member of the WHO-ROK joint mission on MERS outbreak in Korea in June 2015. She also led the Task Force for the Forum on Infectious Disease Research and Development, which is a coalition organization between the government, academic societies, universities and industries in the Republic of Korea from 2014 to 2019. Dr Jee served as a member of the WHO Strategic Advisory Group of Experts for Immunization (SAGE) during 2017-2020 and a member of the Board of Trustees of the International Vaccine Institute during 2016-2019. She serves as a member of the SAGE measles and rubella working group and a member of the hepatitis B expert resource panel in the WHO Western Pacific Region. Dr Jee has served a member of the WHO R&D Blueprint Scientific Advisory Group since 2015 and a member of the National Immunization Technical Advisory Group since 2017. Dr. Jee received her M.D. from the College of Medicine, the Seoul National University, a Diploma in Medical Microbiology from the London School of Hygiene Tropical Medicine, and her Ph.D. from the University of London.

Mark Jit, Ph.D., MPH, is professor of vaccine epidemiology at the London School of Hygiene & Tropical Medicine (LSHTM) and visiting professor at the School of Public Health, University of Hong Kong. His research group focuses on epidemiological and economic modelling of vaccines to support evidence-based public health decision making.

Michael Kremer, Ph.D., is University Professor at the University of Chicago, in the Kenneth C. Griffin Department of Economics. Previously he was Gates Professor of Developing Societies in the Department of Economics at Harvard University. He was named a Young Global Leader by the World Economic
Forum. His recent research examines education and health in developing countries, immigration, and globalization. Professor Kremer is the recipient of the 2019 Sveriges Riksbank Prize in Economic Sciences in Memory of Alfred Nobel, awarded jointly with Abhijit Banerjee and Esther Duflo "for their experimental approach to alleviating global poverty."

**Charles “Ok” Pannenborg, Ph.D.,** served as the World Bank's Chief Health Scientist/Director until his retirement ten years ago, following which he served as a director at PAHO/WHO, as Chairman of the Netherlands Commission on Global Health Research and many boards in the field of global health (R&D, HRH, tropical diseases, biotech, etc.), currently also on the Lancet COVID-19 Commission TF for Global Governance. Prior to joining the World Bank in 1985, he worked for NGOs, UNHCR, WHO in several Asian and African countries, following which he joined the Netherlands Ministry of Health, where he directed strategic health policy, before moving to Washington D.C. During the late 1990s and 2000s he chaired the World Bank/IMF Pandemic Committee. He served on many technical committees of the Netherlands Medical Research Council, more recently on the NASEM Rwanda HRH Committee and he continues to advise international agencies and governments in fields of global health, such as infectious diseases, research & innovation, health workforce systems, pharmaceuticals/vaccines and medical technology, and health financing & economics. Among Dr. Pannenborg’s many publications, his 'A New International Health Order' (1978) was among the earliest global health publications at the time.

**Malik Peiris, DPhil,** is professor of virology at the School of Public Health at The University of Hong Kong. He is a clinical and public health virologist with a particular interest in emerging virus disease at the animal-human interface, including influenza, coronaviruses (SARS-CoV, MERS-CoV, SARS-CoV-2) and others. In 2003, he played a key role in the discovery that a novel coronavirus was the cause of SARS, its diagnosis and its control. Recently he is researching the recently emerged MERS coronavirus and more recently, the newly emerged SARS-CoV-2. He has over 650 peer reviewed research publications in international scientific journals. For his research contributions he was elected a Fellow of the Royal Society of London in 2006 and Foreign Associate of National Academy of Sciences in 2017. He was awarded the Officier de la Legion d’Honneur, France (2017), Mahathir Science Award, Akademi Sains, Malaysia (2007) and Silver Bauhinia Star (S.B.S.), Hong Kong SAR (2008).

**Michael Ryan, M.D.,** has been at the forefront of managing acute risks to global health for nearly 25 years. He served as Assistant Director-General for Emergency Preparedness and Response in WHO's Health Emergencies Programme from 2017 to 2019.

Dr Ryan first joined WHO in 1996, with the newly established unit to respond to emerging and epidemic disease threats. He has worked in conflict affected countries and led many responses to high impact epidemics. He is a founding member of the Global Outbreak Alert and Response Network (GOARN), which has aided the response to hundreds of disease outbreaks around the world. He served as Coordinator of Epidemic Response (2000-2003), Operational Coordinator of WHO’s response to the SARS outbreak (2003), and as WHO’s Director of Global Alert and Response (2005-2011).

He was a Senior Advisor on Polio Eradication for the Global Polio Eradication Initiative from 2013 to 2017, deploying to countries in the Middle East.
He completed medical training at the National University of Ireland, Galway, a Master’s in Public Health at University College Dublin, and specialist training in communicable disease control at the Health Protection Agency in London and the European Programme for Intervention Epidemiology Training.

**Amadou Sall, Ph.D.**, is the CEO of Institut Pasteur de Dakar in Senegal and the chairman of the Global Outbreak Alert and Response Network and director of the WHO collaborating center for Arboviruses and viral hemorrhagic fever. Dr Sall is a virologist with a PhD in Public health. He received his scientific education at Universities Paul Sabatier at Toulouse, Paris Orsay and Pierre et Marie Curie in France. He has also visited several laboratories for his training including Institut Pasteur in Paris, France; Institute of Virology and environmental medicine in Oxford, United Kingdom of Great Britain and Northern Ireland; Center for tropical disease at the University of Texas Medical Branch at Galveston, United States of America (USA) and the Albert Einstein College of Medicine of Yeshiva University, New York, USA. From 2002 to 2004, Dr Sall worked in Cambodia as Head of the viral hepatitis laboratory at the Institut Pasteur Cambodia. From 2010 to 2011, he worked as a Visiting Research Scientist at the Center for Infection and Immunity at the Mailman School of Public Health at Columbia University, New York, USA, on pathogen discovery. His research focuses primarily on diagnostics, ecology and evolution of arboviruses and viral haemorrhagic fevers. Dr Sall has published more than 100 papers and book chapters and has given more than 150 scientific communications at international meetings. Dr Sall is a member of several WHO expert groups, including the Global Outbreak and Alert Response Network and the Strategic Advisory Group of Experts on Immunization. He has also worked as a consultant for the World Organisation for Animal Health.

**Rodrigo Salvado, MPA** is Deputy Director of International Development Finance and contributes to the foundation’s efforts to produce high quality policy analysis that help to (i) optimize the allocation and impact of domestic resources to human development in our priority countries, including how BMFG can best help to realize the potential created by new extractives discoveries in Africa; (ii) better engage with multilateral financing institutions and global forums to advance our strategic priorities; and (iii) provide policy and technical guidance to program and policy teams for operating effectively in a global context. In addition, he also looks at innovative approaches for development financing in middle income countries. Before joining the Foundation, Rodrigo worked for the African Development Bank Group where he was in charge of the Performance Based Allocation System of the African Development Fund and the coordination of the Annual Country Policy and Institutional Assessment (CPIA) exercise. He also provided support to the design and implementation of the African Financial Markets Initiative AFMI and The Making Finance Work for Africa (MFW4A) Partnership. Prior to his job at the AfDB, Rodrigo worked as a policy analyst for the Center for International Development at Harvard University and as a Senior Financial Analyst at the Central American Bank for Economic Integration in Honduras. He holds a Master in Public Administration in International Development from Harvard Kennedy School of Government, a Master in Economics from the Centro de Estudios Monetarios y Financieros in Madrid, and a Bachelor of Science in Economics from the Universidad Torcuato Di Tella in Argentina.

**Peter Sands, MPA** has been the Executive Director of The Global Fund to Fight AIDS, Tuberculosis and Malaria since March 2018. Since June 2015, Mr. Sands has been a Research Fellow at Harvard University,
Joshua Sharfstein, M.D., is Vice Dean for Public Health Practice and Community Engagement and Professor of the Practice in Health Policy and Management at the Johns Hopkins Bloomberg School of Public Health. He is also the Director of the Bloomberg American Health Initiative. Previously, Dr. Sharfstein served as Secretary of the Maryland Department of Health and Mental Hygiene, as Principal Deputy Commissioner of the U.S. Food and Drug Administration, and as Health Commissioner of Baltimore City. In these positions, he pursued creative solutions to longstanding challenges, including drug overdose deaths, infant mortality, unsafe consumer products, and school failure. He is an elected member of the National Academy of Medicine and fellow of the National Academy of Public Administration.

Kanta Subbarao, MBBS, MPH was appointed Director of the WHO Collaborating Centre for Reference and Research on Influenza in 2016. Prior to her arrival in Melbourne, she was Chief of the Emerging Respiratory Viruses Section of the Laboratory of Infectious Diseases, NIAID, National Institutes of Health (NIH) in the United States from 2002-2016 and chief of the Molecular Genetics Section of the Influenza Branch at the US CDC from 1997-2002. Kanta is a virologist and a physician with specialty training in pediatrics and pediatric infectious diseases. She received her M.B.B.S. from Christian Medical College, Vellore in India, completed training in pediatrics and pediatric infectious diseases in the US and earned an M.P.H. in epidemiology from the University of Oklahoma Health Sciences Center. She received postdoctoral training in virology and vaccine development in the Laboratory of Infectious Diseases, NIAID, and NIH. Over the years, her research has focused on newly emerging viral diseases of global importance including seasonal and pandemic influenza, SARS, MERS and now, SARS-CoV-2. Her current research efforts are directed at understanding the biology and immune responses to influenza viruses and vaccines and SARS-CoV-2. She is an internationally recognized leader in the field of emerging respiratory viruses. She is an elected Fellow of the American Academy of Microbiology and the Infectious Diseases Society of America and is a member of the American Society of Microbiology, American Society for Virology and Australasian Virology Society. In her current position as Director of the WHO
Collaborating Centre for Reference and Research on Influenza, she advises the WHO on viruses to be included in annual seasonal influenza vaccines.

Ciro Ugarte, M.D., a national of Peru, received his medical degree from the Mayor National University of San Marcos, Peru. He conducted post graduate studies on Public Health, Emergency and Disasters Medicine, and multiple studies on Mitigation, Preparedness and Response to Emergencies and Disasters. In 1988, Dr. Ugarte was appointed as Deputy Director General at the National Institute of Occupational Health in Peru. In 1989 he was appointed Director General of the Office of National Defense of the Ministry of Health of Peru, position he held until 1999. During this period he also served as: President of the Peruvian Society of Emergency Medicine, Official Representative of the Peruvian Government to the International Committee of the Red Cross, Member of the National Committee of the Peruvian Red Cross Society, consultant of the Office of U.S. Foreign Disaster Assistance (OFDA/USAID) and member of the United Nations Disaster Assessment and Coordination Team (UNDAC). Dr. Ugarte coordinated the United Nations Inter-Agency Disaster Team in Honduras in 1999. He joined PAHO/WHO in 2000 where he served as Sub-regional Advisor for South America, Regional Advisor on Emergency Preparedness, and Director of the Department of Emergency Preparedness and Disaster Relief, and from 2016 as the Director of the Department of Health Emergencies of the Pan American Health Organization. Dr. Ugarte has extensive experience in Prevention, Risk Reduction, Emergency preparedness and Response. He coordinated the implementation of public health measures and health care at national and international levels in case of earthquakes, tsunamis, volcanic eruptions, severe floods, El Nino phenomenon, landslides, hazardous materials incidents, armed conflicts, terrorist attacks, taking of hostages, chemical emergencies, mass gatherings, meetings of Head of States, epidemics of cholera, yellow fever, dengue, malaria, hepatitis, pandemic influenza H1N1, COVID-19, among others. He is the author of numerous publications and articles on vulnerability reduction in health facilities, hospital disaster planning, outbreaks and epidemics preparedness and response, health impact of earthquakes, damage and needs assessment, national contingency planning, safe hospitals and others.

Richard Webby, Ph.D., is a Member of the Department of Infectious Diseases at St Jude Children’s Research Hospital. His research group examines a number of aspects of influenza virus biology with a particular focus on interactions at the human/animal interface. He is Director of the World Health Organization’s Collaborating Center for Studies on the Ecology of Influenza in Animals and Birds and principal investigator of the NIAID-funded the St Jude Center of Excellence in Influenza Research and Response.

James Wood, Ph.D., MSc, is a veterinary epidemiologist who leads the Disease Dynamics Unit in Cambridge and conducts multidisciplinary research on infectious diseases and his research interests are focussed on infectious disease emergence and its control. Ensuring that research impacts on policy is a particular interest. He has worked on potentially zoonotic viruses in African bats for much of the last 15 years since he came to Cambridge and has widely published on risks of disease from wildlife. He is one of the champions of the Cambridge Africa programme which works to promote equitable relationships in research between academics based in Cambridge and those in sub-Saharan Africa.
Wenqing Zhang, M.D., has headed the Global Influenza Program of the World Health Organization (WHO) in its headquarters in Geneva, Switzerland, since November 2012. In this role, Dr. Zhang provides leadership and coordinates global activities on influenza surveillance, virus monitoring, detection of emerging novel viruses, risk assessment and evidence for policies, vaccine virus, and pandemic preparedness including pandemic influenza vaccine response. From 2002 to 2012, Dr. Zhang coordinated the WHO Global Influenza Surveillance and Response System (GISRS), building a functional global system of surveillance, preparedness, and response. In response to 2009 A (H1N1) influenza pandemic, Dr. Zhang directed the laboratory response and capacity aspects of WHO response. Before joining WHO, Dr. Zhang worked for 9 years in the Chinese Academy of Preventive Medicine, Ministry of Health on tuberculosis, schistosomiasis, and iodine deficiency disorder projects with WHO, the World Bank, the United Nations Children’s Fund, and the United Nations Industrial Development Organization. Dr. Zhang has an M.D., with postgraduate training in system evaluation and epidemiology, and holds a bachelor’s degree in biomedical engineering.